E-resources
-
Mead, Adam J.; Milojkovic, Dragana; Knapper, Steven; Garg, Mamta; Chacko, Joseph; Farquharson, Mira; Yin, John; Ali, Sahra; Clark, Richard E.; Andrews, Chris; Dawson, Meryem Ktiouet; Harrison, Claire
British journal of haematology, July 2015, 2015-Jul, 2015-07-00, Volume: 170, Issue: 1Journal Article
Summary Myelofibrosis is characterized by splenomegaly and debilitating constitutional symptoms that negatively impact patients’ quality of life. ROBUST, a UK, open‐label, phase II study, evaluated the safety and efficacy of ruxolitinib in patients with myelofibrosis (N = 48), including intermediate‐1 risk patients. The primary composite endpoint was the proportion of patients achieving treatment success ≥50% reduction in palpable spleen length and/or a ≥50% decrease in Myelofibrosis Symptom Assessment Form Total Symptom Score (MF‐SAF TSS) at 48 weeks. This was the first time that efficacy of ruxolitinib in myelofibrosis has been evaluated based on these criteria and the first time the MF‐SAF was used in a population of patients solely from the United Kingdom. Overall, 50% of patients and 57% of intermediate‐1 risk patients, achieved treatment success; reductions in spleen length and symptoms were observed in all risk groups. The majority of patients (66·7%) experienced ≥50% reductions from baseline in spleen length at any time. Improvements in MF‐SAF TSS were seen in 80·0%, 72·7%, and 72·2% of intermediate‐1, intermediate‐2, and high‐risk patients, respectively. Consistent with other studies of ruxolitinib, the most common haematological adverse events were anaemia and thrombocytopenia. Results indicate that most patients with myelofibrosis, including intermediate‐1 risk patients, may benefit from ruxolitinib treatment.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.